10.22.20
Press Release
October 22, 2020 Dear Fellow Shareholders, We hope this letter finds you and your families safe and healthy. Given that we continue to live in unprecedented times, faced with uncertainty and unique challenges, John and I thought it was appropriate to reach out with an update on the company’s progress. Achieve remains committed to prioritizing…
/Read More10.08.20
Press Release
SEATTLE, Wash and VANCOUVER, British Columbia, October 8, 2020 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it has been invited to present at the MicroCap Rodeo Best Ideas Bowl, which is being held…
/Read More10.07.20
Press Release
Designed to Assess the Efficacy and Safety of 3 mg Cytisinicline Three Times Daily Dosing Compared to Placebo Phase 3 ORCA-2 Trial to Enroll 750 Smokers Across 15 Clinical Trial Sites in the United States SEATTLE, Wash and VANCOUVER, British Columbia, October 7, 2020 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company…
/Read More09.30.20
Press Release
SEATTLE, Wash. and VANCOUVER, British Columbia, September 30, 2020 – – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced the promotion of John Bencich to Chief Executive Officer. Mr. Bencich has been serving as Achieve’s Chief Financial and Operating…
/Read More09.18.20
Press Release
Subjects in the Cytisinicline Arm Were 55% More Likely to Quit Smoking at 6 Months Compared to Subjects Who Received Varenicline Significantly Fewer Overall Adverse Events Were Reported in Cytisinicline-Treated Subjects (p<0.001) Cytisinicline U.S. Phase 3 Trial Expected to Begin in Fourth Quarter 2020 SEATTLE, Wash and VANCOUVER, British Columbia, September 18, 2020 — Achieve…
/Read More